Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases (r/r AID)

NCT07095075 is registered in ClinicalTrials.gov with Nanjing Legend Biotech Co. as lead sponsor.

NCT NCT07095075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07095075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases (r/r AID)
Lead sponsor
Nanjing Legend Biotech Co.
Phase
Phase 1
Overall status
Recruiting
Start date
October 14, 2025
Completion date
December 31, 2029
Enrollment
36 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory autoimmune diseases